Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

7-1-2015

Efficacy of WHO recommendation for continued breastfeeding
and maternal cART for prevention of perinatal and postnatal HIV
transmission in Zambia
Mary S. Ngoma
University of Zambia

Amita Misir
Western University, amita.misir@lhsc.on.ca

Wilbroad Mutale
University of Zambia

Emmanuoil Rampakakis
Université McGill

John S. Sampalis
Université McGill

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Ngoma, Mary S.; Misir, Amita; Mutale, Wilbroad; Rampakakis, Emmanuoil; Sampalis, John S.; Elong,
Angela; Chisele, Sam; and Mwale, Abel, "Efficacy of WHO recommendation for continued breastfeeding
and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia" (2015).
Paediatrics Publications. 1855.
https://ir.lib.uwo.ca/paedpub/1855

Authors
Mary S. Ngoma, Amita Misir, Wilbroad Mutale, Emmanuoil Rampakakis, John S. Sampalis, Angela Elong,
Sam Chisele, and Abel Mwale

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/1855

Ngoma MS et al. Journal of the International AIDS Society 2015, 18:19352
http://www.jiasociety.org/index.php/jias/article/view/19352 | http://dx.doi.org/10.7448/IAS.18.1.19352

Research article
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Abstract
Introduction: To prevent mother-to-child transmission (MTCT) of HIV in developing countries, new World Health Organization
(WHO) guidelines recommend maternal combination antiretroviral therapy (cART) during pregnancy, throughout breastfeeding
for 1 year and then cessation of breastfeeding (COB). The efficacy of this approach during the first six months of exclusive
breastfeeding has been demonstrated, but the efficacy of this approach beyond six months is not well documented.
Methods: A prospective observational cohort study of 279 HIV-positive mothers was started on zidovudine/3TC and lopinavir/
ritonavir tablets between 14 and 30 weeks gestation and continued indefinitely thereafter. Women were encouraged to
exclusively breastfeed for six months, complementary feed for the next six months and then cease breastfeeding between 12
and 13 months. Infants were followed for transmission to 18 months and for survival to 24 months. Text message reminders and
stipends for food and transport were utilized to encourage adherence and follow-up.
Results: Total MTCT was 9 of 219 live born infants (4.1%; confidence interval (CI) 2.27.6%). All breastfeeding transmissions
that could be timed (5/5) occurred after six months of age. All mothers who transmitted after six months had a six-month
plasma viral load 1,000 copies/ml (p B0.001). Poor adherence to cART as noted by missed dispensary visits was associated
with transmission (p 0.04). Infant mortality was lower after six months of age than during the first six months of life (p 0.02).
The cumulative rate of infant HIV infection or death at 18 months was 29/226 (12.8% 95 CI: 7.520.8%).
Conclusions: Maternal cART may limit MTCT of HIV to the UNAIDS target of B5% for eradication of paediatric HIV within the
context of a clinical study, but poor adherence to cART and follow-up can limit the benefit. Continued breastfeeding can prevent
the rise in infant mortality after six months seen in previous studies, which encouraged early COB.
Keywords: breastfeeding transmission of HIV; vertical transmission; option B; infant survival; efficacy of WHO guidelines;
perinatal transmission of HIV.
To access the supplementary material to this article please see Supplementary Files under Article Tools online.
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Introduction
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
has set a global plan to reduce HIV infections among
HIV-exposed children to below 5% by 2015 and to keep their
HIV-positive mothers alive through the provision of antiretroviral medication [1]. Despite the risk of mother-to-child
transmission (MTCT) of HIV, in many developing countries,
no acceptable, feasible, affordable, sustainable or safe alternative to breastfeeding exists [24]. Reaching the 5% target
will require prevention of antepartum, intrapartum and postpartum transmission.
In the absence of antiretroviral prophylaxis, MTCT is lower
during the first six months of life in exclusively breastfed

(EBF) infants compared to those who mixed feed [5,6].
Multiple studies have shown that maternal combination
antiretroviral therapy (cART) can reduce postpartum MTCT
for up to six months of EBF [79].
In HIV-exposed children, infant mortality and morbidity
(e.g. failure to thrive (FTT), diarrhoea, pneumonia, malaria and
tuberculosis) are increased after early cessation of breastfeeding (COB) (at 46 months) [913]. Therefore, in 2010 the
World Health Organization (WHO) issued new recommendations which include EBF for 6 months followed by complementary feeding (CF) (defined as continued breastfeeding
with the addition of solid or semi-solid foods) to 12 months
of age and followed by gradual COB [2,14]. Maternal cART is
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recommended during pregnancy and postpartum breastfeeding to prevent MTCT (PMTCT). For women whose CD4 cells are
B500 cells/ml, on-going maternal cART after COB is recommended to protect the mothers health [15]. For women whose
CD4 500 cells/ml, the WHO recommends either option B
where maternal cART is discontinued after COB or Option B
where maternal cART is continued indefinitely [15]. Unfortunately, there are only limited data on the impact of maternal
cART on infant adverse events and PMTCT while breastfeeding beyond six months of age. Therefore, the quality of the
supporting evidence for the new WHO guidelines is still noted
as low to moderate [2,14,15]. We, therefore, carried out a
study to assess the efficacy and safety of continued breastfeeding while the mother receives cART.

Methods
This was a prospective observational cohort study. Recruitment took place from December 2008 to December 2009 at
the Chelstone Public Clinic in Lusaka, Zambia.
Inclusion criteria were: age ]15 years, HIV seropositivity,
confirmed pregnancy with the ability to initiate cART at
1430 weeks gestation, intention to EBF for six months,
ability to give informed consent and to attend follow-up visits.
Exclusion criteria were previous cART (other than single-dose
nevirapine or 51 month of zidovudine for PMTCT prophylaxis,
which were not contraindications), known major illness likely
to influence pregnancy outcome or place the participant
at increased risk for adverse events from cART, including
diabetes, severe renal, liver or heart disease, active tuberculosis, severe anaemia (Hgb B8 g/dl) or continuing therapy with
medications, which are contraindicated for co-administration
with ritonavir/lopinavir.
All mothers received zidovudine (ZDV) 300 mg/lamivudine
(3TC) 150 mg (Combivir†, ViiV healthcare, Middlesex, UK) bid
and lopinavir 200 mg/ritonavir 50 mg (trade name Aluvia† in
Zambia, Abbvie, Chicago, IL) two tablets bid initiated between
gestational age (GA) 14 and 30 weeks, and continued during
labour, breastfeeding and COB. Women were enrolled in the
national cART programme upon COB and were continued
indefinitely on cART regardless of CD4 count (as per WHO
option B). Lopinavir/ritonavir was used, as efavirenz was not
recommended during pregnancy at the time of this study [16],
and nevirapine was contraindicated for the majority of women
due to high baseline CD4 [17]. This approach allowed rapid
initiation of therapy prior to CD4 results. Infants received oral
ZDV for five days postpartum. EBF was encouraged to 6
months, with CF starting at 6 months and continued to 12
months, followed by the recommendation to cease breastfeeding between 12 and 13 months. Women received ongoing counselling regarding medication adherence, text
message reminders for clinic visits and stipends for food and
transport (30,000 kwacha, equivalent to $6US/visit).
Mothers were screened antepartum for syphilis using a nontreponemal test and were given multivitamins. Sexually
transmitted diseases were diagnosed and treated syndromically as per national guidelines. Mothers received counselling
on infant nutrition. GA dating was based on recall of last
menstrual period. Follow-up visits took place antepartum at
4 weeks after enrolment, 36 weeks gestation; at birth;

at postpartum infant ages 2, 6 weeks and 3, 6, 9, 12, 15 and
18 months. Infant dried blood spots for PCR were obtained at
all postpartum visits. Infant survival data were also obtained at
24 months. Maternal plasma viral loads and drug resistance
genotyping were assayed on all transmitting mother-infant
pairs using standard techniques [18,19] (see Supplementary
files). Maternal plasma viral load was also assayed at birth and
six months on a convenience sample of 96 non-transmitting
mothers.
Standard breastfeeding definitions were used for the study
and were obtained from UNICEF [20]:
Exclusive breastfeeding (EBF): Only breast milk
medicines/vitamins.
Mixed feeding: Breast milk and non-human milk
(including formula) and/or semi-solid/solid foods
before six months.
Complementary feeding (CF): Continued breastfeeding with the addition of solid or semi-solid foods
beyond six months.
Replacement feeding: No breast milk at all, fed only
non-human milk or semi-solids/solids.
Ethical approval for the study was obtained from the
research ethics boards of the University of Zambia in Lusaka
and also Lakeridge Health Corporation in Canada. All mothers
provided written informed consent. The study funders had
no role in the design of the protocol, conduct of the study,
the analysis of data or the writing of the manuscript.
Statistical methods
The primary outcome of interest was the rate of HIV-free
survival after an extended period (i.e. 12 months) of
breastfeeding followed by gradual COB. Secondary outcomes
of interest included HIV transmission rates and mortality
particularly as they corresponded to the different time periods
of exclusive breastfeeding (06 months), CF (612 months)
and COB (1218 months). The incidence of HIV transmission
and death was described with the corresponding incidence
rates up to 18 months post-partum for the above time periods.
Denominators for these incidence rates include only those
infants who remained at risk for transmission (i.e. were known
to be HIV-uninfected and surviving) at the beginning of each
relevant time period.
For all analyses, patients who were lost to follow-up were
not included in the analysis for the periods when they
were not available. This was decided in order to prevent
these patients from being inadvertently considered as nontransmitting or surviving and thus artificially inflating efficacy.
Categorical variables were summarized using frequency
distributions and percentages, whereas continuous variables
were described with the mean and standard deviation.
We used independent samples t-test to assess statistical
differences in (i) maternal age, maternal CD4 at birth and
infant GA at birth between women lost to follow-up postpartum and those completing 24 months of follow-up and (ii)
mean viral load between transmitting and non-transmitting
mothers. We used Pearson’s chi-square test to assess
statistical differences in (i) the viral load categories at six
months between transmitting and non-transmitting mothers;

2

Ngoma MS et al. Journal of the International AIDS Society 2015, 18:19352
http://www.jiasociety.org/index.php/jias/article/view/19352 | http://dx.doi.org/10.7448/IAS.18.1.19352

(ii) infant mortality based on presence or absence of low
birthweight and (iii) HIV transmission between women missing vs. not missing a dispensary visit. Changes in viral load and
viral load detection over six months of treatment were
assessed with the paired t-test and the McNemar test,
respectively. The incidence of HIV transmission and death
was described with the incidence rate and the incidence
rate ratio and the corresponding 95% confidence intervals
(95% CI). A comparison of different time intervals with respect
to these outcomes was performed using the person-time
chi-square (x2P-T) test [21,22].
Predictors of adverse event count by time interval were
investigated using a saturated Poisson regression model
where time interval and individual person follow-up time
were incorporated as adjusting covariates. Given that this
was a saturated model, goodness of fit was not assessed.
Over dispersion was examined by dividing the Pearson statistic
by its degrees of freedom and was corrected, as required,
by inflating accordingly the covariance matrix.
All analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC), and all analyses were performed using a 0.05
significance level.

Results
Study population
Clinical baseline characteristics of the cohort are presented in
Table 1.
Transmission
Transmission status at follow-up is presented in Figure 1.
Overall, when considering all 231 live births, HIV status was
known at 18 months or at the last scheduled test interval
before their death (whichever came first) for 201/231
(87.0%). There was no difference between the women who
were lost to follow-up postpartum and those who completed
24 months of follow-up when compared by maternal age
(p 0.55), maternal CD4 at birth (p 0.89) or infant GA at
birth (p 0.946). A total of 9/219 (4.1%; 95% CI: 2.27.6%)
infants acquired HIV during the study period. There was
a trend towards a higher transmission rate/100 personweeks during 618 months (0.0529/100 person-weeks) when
Table 1. Maternal baseline characteristics (live born infants only)
Maternal baseline characteristics

Available n

(N231)

Maternal age, years, mean (SD)

226

28.1 (5.5)

Gestational age (GA) at birth, weeks,

229

38 (3.5)

Sexually transmitted infections (STIs), n (%)

225

41 (18%)

Multiple birth, n (%)

225

7 (3%)

CD4 B350 at study entry, n (%)

209

125 (60%)

CD4 B200 at study entry, n (%)
CD4 count, mean (SD)

209
209

45 (22%)
353.8 (207.1)

Anaemia (haemoglobin B10 g/dl), n (%)

225

mean (SD)

55 (24%)

Note: Detailed socio-demographic data are available in Supplementary Table 1.

compared to six weeks to six months (0/100 person-weeks;
p 0.167).
Details of the individual transmissions are found in Supplementary Table 2. Baseline maternal CD4 count (B200 vs.
200; odds ratio, OR B350 vs. 350, OR B500 vs. 500)
was not correlated with infant mortality or postpartum
transmission (data not shown).
Treatment failure and late HIV transmission
Five of five women who transmitted after six months had a
plasma viral load (VL) 1,000 at six months (range 3,252
459,866; mean 4.75 log10, SD 0.82). In comparison, mean viral
loads at six months in the 96 non-transmitting mothers tested
were lower (mean 0.61 log10 SD 1.4; pB0.0001). Twelve of
96 (12.5%) non-transmitting mothers had a VL 1,000
(p B0.001) and 16/96 (16.7%) had a VL 50 at six months
(p B0.001). Including all transmitting and non-transmitting
mothers, more mothers had a detectable VL ( 50) at birth
(40 of 99 (40.4%)) than at six months (p0.002), and mean
Log10 viral load at six months (1.21, SD 1.94) was not higher
than at birth (1.25, SD1.73; p0.86). Data available on seven
of nine transmissions showed one transmission (antepartum)
to be associated with resistance to the cART regimen (K65R in
mother and infant; Supplementary Table 3).
Mortality
Four of 279 (1.4%) mothers died including one maternal
death with accompanying miscarriage/foetal death. Details
of individual infant and maternal deaths are given in
Supplementary Tables 4 and 5.
Two hundred and eleven of 231 (91.3%) live born infants
had 24-month survival data, the remainder being lost to
follow-up. Cumulative postnatal mortality was 25/231 live
births (10.8%; 95% CI: 6.814.8%). Data on cumulative rate
of HIV infection and/or death were available for 226 infants
with a cumulative rate of 29/226 (12.8%; 95% CI: 7.520.8%)
(includes 20 deaths of HIV-uninfected infants, 5 deaths in
HIV-infected infants and 4 transmissions in surviving infants).
HIV-uninfected infant death rate was highest in the first six
months of life, falling during the second six months with no
evidence of any rise after COB at 1 year (Table 2).
Using the same intervals as in the recent BAN study, which
showed an increase in HIV-uninfected infant mortality with
COB at 28 weeks [9], HIV-uninfected infant mortality in our
cohort fell from 0.2183/100 person-weeks (95% CI: 0.1162
0.626) during the first 28 weeks of life to 0.0755/100 personweeks (95% CI: 0.01560.2016) during weeks 2948 (incidence rate ratio 0.346 (95% CI: 0.09831.22); p0.04).
Total mortality (HIV-infected and -uninfected infants) was
also higher in the first six months of life 0.2839/100 personweeks (95% CI: 0.15890.4564) than between 6 and 12 months
0.0813/100 person-weeks (95% CI: 0.0220.1933; incidence
rate ratio0.286 (95% CI: 0.069, 0.8989) (p0.02)).
Maternal adherence
Self-reported adherence to breastfeeding recommendations
was requested at each visit with full data to COB or death
being available on 205/231 infants (88.7%). Adherence was
high with 92.8% EBF until six months and 79% CF thereafter.
Only 4.5% had ceased breastfeeding completely at 6 months
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Figure 1. Transmission status follow-up on livebirths and survivors.
$
Three hundred and eighty-four pregnant women were approached, of which 80 were not eligible (due to presentation outside of 14 30 weeks
gestation) and 25 declined enrolment, leaving 279 women who were recruited. Of the 279 enrolled women, 45 of 279 (15%) defaulted before
birth, leaving 234 women. Of these 234 women, 8 had stillbirths and 226 had livebirths. These 226 mothers delivered 231 liveborn infants (five
pairs of twins were included). *Two infants HIV positive at birth so no longer at-risk for transmission at start of time interval, therefore removed
from denominator. **Infant became HIV positive1 infant died between birth and 6 weeks, so no longer at-risk for transmission at start of time
interval, therefore removed from denominator.



and 97.8% had ceased breastfeeding by 15 months (Figure 2)
(age range of COB 1.517 months).
Self-reported adherence to taking cART was unreliable as
it correlated poorly with attendance at dispensary visits (data
not shown). Thirty-six of 226 women (15.9%) missed at least
one dispensary visit (i.e. were greater than two weeks late
for a scheduled visit and therefore would have had a drug

holiday due to medication shortage). Four of 35 (11.4%)
women who missed a visit vs. 5 of 184 (2.7%) women who
did not miss a visit transmitted HIV (p 0.038).
Maternal and infant adverse events
In order to compare adverse events during different time
periods, HIV-infected and HIV-uninfected infants are analyzed
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Table 2.

Death incidence rate ratio by time to event for infants who were HIV uninfected
Incidence rate

Time interval
(month)a

Number of deaths

(per 100 person-week)

Incidence rate ratio

95% CI of IRR

p

(06)

12

0.2346

1.0000

NA

NA

(612)

4

0.0838

0.3570

(0.1148, 1.1102)

0.03952

(1218)

2

0.0433

0.1847

(0.0412, 0.8284)

0.00160

(1824)

2

0.0457

0.1947

(0.0434, 0.8735)

0.00228

Note: aPatients contributed the respective person-time corresponding to each time period provided they were known to be remaining at risk of
death during that time period. Therefore, those who were lost to follow-up at any point did not contribute person-time for subsequent time
periods. Mortality at each time interval is compared with that at the first time interval (06 months). Confidence intervals were determined
considering a Poisson distribution for the number of deaths. NA, not applicable.

separately as in previous studies [9]. In HIV-uninfected infants
(Table 3), FTT was greatest in the first six months of life
(p B0.001), the rates of diarrhoea rose after six months of
age (during the period of CF) when compared with the first
six months of life (EBF; p B0.001) and the rates of respiratory
tract infections rose during the period of COB (1218 months
of age) when compared with the periods of EBF (06 months)
and CF (612 months; pB0.001 for both comparisons). The
number of HIV-infected infants was small making estimates
of the incidence of adverse effects in this group unreliable
(see Supplementary Table 6). Maternal adverse events are
in Supplementary Table 7.

Discussion
This study provides an estimate of the real-world efficacy
of continued maternal cART. The government of Malawi
reviewed their experience of the efficacy of Option B, but
HIV status was documented at 12 months or beyond on only
54% of infants leading to an inability to make a reliable

estimate of efficacy [23]. Furthermore, a recent review did
not find any reports which were able to assess late MTCT
through the end of 12 months of breastfeeding using option
B or B [24]. We believe that our study is the first to report
rates of MTCT at 18 months of age.
Predictive models to estimate the efficacy of different
national programmes to lead to population wide HIV MTCT
rates B5% have suggested that very high population coverage
with maternal ARVs will be necessary [25,26]. Our data
showing 4.1% MTCT using continued maternal cART within
the context of a clinical study suggest that even at 90%
enrolment in ARV programmes nationally, achieving a population wide MTCT rate of less than 5% may be challenging
[25]. Furthermore, loss to follow-up antepartum (15%) and
postpartum (13%) would have led to a significant number
of women discontinuing cART. This occurred despite using
adherence counselling, food and transportation stipends and
text messaging reminders to enhance follow-up. Therefore,
the true intent-to-treat transmission rate would likely be

Figure 2. Type of feeding over time.
Note: definitions for feeding types [24].
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Table 3. Total infant adverse events (excluding HIV-infected infants)
Time perioda

pb

06 months

612 months

1218 months

018 months

612 vs.

1218 vs.

1218 vs.

(n, R)

(n, R)

(n, R)

(n, R)

06 months

06 months

612 months

Diarrhoea

18 (0.36)

55 (1.16)

61 (1.33)

134 (0.94)

0.00002

B0.00001

0.45966

Respiratory infection

12 (0.24)

11 (0.23)

57 (1.24)

80 (0.56)

0.94240

B0.00001

B0.00001

Failure to thrive

88 (1.75)

34 (0.72)

33 (0.72)

155 (1.09)

0.00001

0.00001

0.98412

Rash

71 (1.42)

15 (0.32)

14 (0.30)

100 (0.70)

B0.00001

B0.00001

0.92923

Candidiasis

14 (0.28)

6 (0.13)

0 (0.00)

20 (0.14)

0.11281

0.02262

0.08464

Adverse event

Malaria
Nonspecific infection
Tuberculosis

6 (0.12)

2 (0.04)

9 (0.20)

17 (0.12)

0.22568

0.35831

0.05407

14 (0.28)
0 (0.00)

0 (0.00)
2 (0.04)

3 (0.07)
0 (0.00)

17 (0.12)
2 (0.01)

0.02125
0.28298

0.02517
0.96486

0.19028
0.30926

Note: Rates are based on per 100 person-weeks. aPatients contributed the respective person-time corresponding to each time period. bp-Values
were computed using a Poisson regression.

higher than 5% even within this study cohort. Very high ‘‘realworld’’ rates of loss to follow-up in pregnant and breastfeeding
women on cART have been found in other studies [2729]
and so we feel that our data reflect real-world efficacy.
The 95% CI for the MTCT rate was 2.27.6%, and so further
studies with larger cohorts will be required to confirm the rate
of MTCT using continued maternal cART.
Six episodes of post-partum transmissions occurred and
of these, all five for which data were available to determine
timing occurred after six months of age. Adherence to maternal cART was poor or questionable in all five women in our
cohort who transmitted after six months (Supplementary
Table 2). The transmission of a K65R resistance mutation
leading to potential failure of future cART in one infant is
concerning. A meta-analysis of 51 studies found that only 53%
of women had adequate adherence to ARVs in the postpartum
period [30].
When analyzed as a continuous variable, CD4 count was
not found to be correlated to HIV transmission or infant death
in the postpartum period (data not shown). Our low event rate
likely led to a lack of sensitivity in identifying a relationship.
Only the maternal VL measured at six months was predictive
of subsequent HIV transmission. This is consistent with data
involving heterosexual transmission of HIV, which demonstrated the importance of viral load in risk of transmission
[31]. Our data suggest that measurement of maternal VL at
six months of age may help to identify infants at higher risk
of late transmission. Patients displaying virologic failure, or
patients who have missed dispensary visits, may benefit from
further counselling regarding ARV adherence, both for the
mother’s health and to prevent MTCT although this approach
would require further study to confirm. Maternal adherence
to treatment may have been improved by using a daily rather
than a twice daily cART regimen [32]. It is notable, however,
that twice daily ZDV/3TC is still a preferred option in both
the US and British treatment guidelines for pregnant women
[33,34].
Our data support the logical premise that poor adherence
leading to an elevated maternal viral load appears to be
the main factor responsible for post-partum transmission.

We base this on the observation that not only elevated
maternal viral load but also missed dispensary visits were
associated with transmission. However, the hypothesis that
there may be something inherently different about the EBF
(06 months) vs. the CF and COB (618 months) periods
that makes the latter particularly susceptible to MTCT in the
setting of an elevated viral load is also possible. The trend
towards a higher transmission rate/100 person-weeks during
618 months when compared to 6 weeks to 6 months
(p 0.167) is suggestive. In addition, when including transmitting and non-transmitting mothers, more mothers had a
detectable VL ( 50) at birth than at six months (p 0.002),
and mean Log10 viral load at six months was not different
from that obtained at birth, which would lead one to expect
that there would be equivalent or more transmissions in the
0 to 6 months vs. 6 to 18 months period if VL level was the
sole factor responsible for MTCT, which was not seen in our
results. The mechanism of this potential inherent difference
between the EBF (06 months) and CF/COB (618 months)
period remains speculative but may include ingestion of
contaminated water, fluids and food, which may lead to gut
mucosal injury and disruption of immune barriers which has
been proposed for the increased MTCT seen in previous
studies [35,36] that identified a higher transmission rate
with mixed feeding compared with EBF. This hypothesis
should be interpreted with caution, however, given our low
event rate, our VL comparator convenience sample being
limited to 96 non-transmitting mothers and that there was a
trend but not a statistically significant difference in transmissions in the 0 to 6 months vs. 6 to 18 months time periods.
Our HIV-uninfected infant mortality rate was highest in the
0 to 6 months’ time period (12 deaths) vs. any other time
period (8 deaths in 618 months time period). Worldwide,
a child’s risk of dying is highest in the first 28 days of life
[37]; our results were consistent with this, with 8 of 12 HIVuninfected infant deaths in the 06 month time period
occurring in the first 28 days of life (Supplementary Table 5).
In addition, the well-known ‘survivor bias’ would also predict this drop in mortality as time advances. Comparison of
mortality rates in a specific time period (i.e. 618 months) to
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a historic time period (i.e. 06 months) is biased in the
direction of making the later mortality rate appear lower
even though it is being compared within the same population. This is because of the premise that the population that
is remaining at the later time period is actually a substantively different population by virtue of the fact that infants
who have survived 6 months have already been selected
out as being healthier/more resistant to mortality. The fact
that this survivor bias was not seen in previous studies is
interpreted as a complication of the early COB in those
studies [9,12]. By contrast, in our cohort, the total and HIVuninfected infant mortality rates fell significantly after six
months, which suggests a protective effect of on-going
breastfeeding.
Our absolute rate of infant mortality in the first six months
of life was higher than that seen in the recently published BAN
study in Malawi [9]. This difference may reflect the reported
higher under-5 mortality rate in Zambia when compared to
Malawi, the aetiology of which is probably multifactorial
[38]. This fact, however, should not change the withinpopulations comparison of under and over 28-week death
rates seen, which showed a significant increase in mortality
after 28 weeks in the Malawi population which utilized
early COB (from 0.065 to 0.12/100 person-weeks) vs. a
decrease in mortality after 28 weeks in our cohort (from
0.2183 to 0.0755/100 person-weeks; p 0.007). Overall,
this would suggest that the difference in infant-feeding
practices between the two studies is a very plausible explanation for the demonstrated reversal in pattern of the
change in mortality at six months. Nevertheless, comparisons
in outcomes between different cohorts need caution in their
interpretation.
Our infant FTT was significantly higher during EBF when
compared to later time periods (Table 3). We believe that
this is also likely due to a survivor bias, and this also impacts
early death rates as about 45% of all child deaths are linked to
malnutrition [37]. After infants are developmentally advanced
enough to accept significant amounts of semi-solid/solid foods
(typically after six months), the available options to provide
safe, high-caloric and nutrient-rich foods expand significantly.

Conclusions
Continued maternal cART can achieve the global UNAIDS
target of B5% MTCT for eradication of paediatric HIV within
the context of a clinical study but loss to follow-up and poor
adherence to therapy may limit the benefit. Continued
breastfeeding may prevent the rise in infant mortality at six
months seen with early COB. These data will help to inform
policy decisions regarding implementation of the new WHO
guidelines.
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